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Abstract 
Alzheimer’s disease (AD) is the most common of the neurodegenerative diseases. Recent diagnostic 
criteria have defined a preclinical disease phase during which neuropathological substrates are thought to 
be present in the brain. There is an urgent need to find measurable alterations in this phase as well as a 
good peripheral biomarker in the blood. We selected a cohort of 100 subjects (controls = 47; preclinical 
AD = 11; patients with AD = 42) and analyzed whole blood expression of 20 genes by quantitative 
polymerase chain reaction. The selected genes belonged to calcium-signaling, senescence and autophagy, 
and mitochondria/oxidative stress pathways. Additionally, two genes associated with an increased risk of 
developing AD (CLU and BIN1) were also analyzed. We detected significantly different gene expressions 
of BECN1 and PRKCB between the control and the AD groups; and, of CDKN2A between the control and 
the preclinical AD groups. Notably, these three genes are also considered tumor suppressor (CDKN2A 
and BECN1) or tumor promoter (PRKCB) genes. Gene-gene expression Pearson correlations were 
computed separately for controls and patients with AD. The significant correlations (p<0.001) were 
represented in a network analysis with Cytoscape tool, which suggested an uncoupling of mitochondria-
related genes in AD group. Whole blood is emerging as a valuable tissue in the study of the 
physiopathology of AD. 
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Introduction 
Alzheimer’s disease (AD) is the most common of the neurodegenerative diseases. It is characterized by 
an initial alteration of episodic memory that progresses to dementia in later stages. Most patients with AD 
are sporadic, with evidence of a complex multifactorial etiology in which genetic and environmental 
factors contribute to the disease development. Many genome-wide association studies have tried to link 
the risk of suffering AD with certain genes. Consequently, we know that the apolipoprotein E (APOE) 
gene (specifically the 4 allele) has an important role, with other important susceptibility loci being the 
clusterin (CLU) and bridging integrator 1 (BIN1) genes. Indeed, single-nucleotide polymorphisms in these 
genes are associated with increased risk of developing AD (http://www.alzgene.org/). 
In AD, the underlying neuropathological findings are the extracellular deposition of β-amyloid (Aβ) 
peptide plaques, intracellular neurofibrillary tangles (consisting of hyperphosphorylated aggregates of the 
microtubule-associated protein tau) and selective neuronal loss [1]. Thus, biomarkers of brain amyloid 
deposition, such as the reduction of Aβ42 in cerebrospinal fluid (CSF) or increased tracer retention on 
amyloid positron emission tomography (PET) have been described as early biochemical hallmarks of the 
disease. Other CSF biomarkers, such as increased levels of total tau protein (t-tau) and phosphorylated tau 
at threonine 181 (p-tau), are altered later in the progression of the disease and indicate neuronal injury [2]. 
Recent consensus criteria [3] have defined the preclinical stage of AD (Pre-AD) as patients with normal 
cognition, but abnormal amyloid biomarkers. Nevertheless, although such patients can be defined as Pre-
AD, this does not mean that all of them will develop the clinical symptoms of the disease, nor can it 
predict when it might happen. In that sense, diagnosis of AD cannot be established in the Pre-AD stage, 
even though such patients are part of both observational research studies and clinical trials aiming to 
prevent or delay disease onset. 
Several studies have tried to identify a gene expression signature in the peripheral blood that has 
diagnostic value for the detection of AD [4-8]. Although the validity of the blood transcriptome for the 
early diagnosis of AD has yet to be tested extensively, gene transcriptional profiles in the blood can 
reflect the complex pathophysiological status of AD, suggesting the potential of blood as a tissue for 
investigating causative factors, disease mechanisms, biomarkers, and novel therapeutic targets for AD [9-
10,8]. Genes found to be expressed differently in the blood in AD are involved in biological pathways 
that have been associated with oxidative stress, mitochondrial dysfunction, immune activation, 
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inflammation, apoptosis, cell cycle, transcription, ion channels, extracellular matrix components, 
neurological function, and other functional categories [4-6,8]. 
In a whole-genome brain transcriptome profiling study in patients with AD, we previously described that 
calcium signaling was the most overrepresented altered pathway in the AD brain [11]. Thus, we wanted 
to explore if we could detect differences in the expression of genes related to this pathway in the 
peripheral blood. Moreover, mitochondrial dysfunction and autophagy have been related to the 
physiopathology of AD [12-13]. Therefore, we were also interested in studying the expression of genes 
from these pathways in the blood. 
The aim of this study was to investigate if gene expression in the peripheral blood reflects AD-related 
changes in calcium-signaling, senescence and autophagy, and mitochondrial function/oxidative stress. 
Additionally, we searched for changes in the expression of two genes associated with an increased risk of 
developing AD (CLU and BIN1). These two genes do not belong to any of the biological pathways 
mentioned above, although CLU can be related to the response to elevated platelet cytosolic Ca2+. We 
carefully selected our cohort, taking into account clinical and neuropsychological information together 
with the levels of AD biomarkers in the CSF (A42, t-tau, and p-tau). We specifically included a group of 
Pre-AD subjects, which to our best knowledge have not been studied in previous gene expression studies 
in the peripheral blood. In addition to assessing the differences in gene expression between clinical 
groups, we derived correlation networks for the studied genes to identify potential differences between 
patients with AD and controls. 
 
Materials and methods 
Subjects 
Study subjects (total N = 100) were consecutively recruited at the Alzheimer’s Disease and Other 
Cognitive Disorders Unit of the Hospital Clínic de Barcelona. Written informed consent was obtained for 
all subjects. Participants received a complete clinical and neuropsychological examination, magnetic 
resonance imaging, and a lumbar puncture. The determination of CSF biomarkers of AD (Aβ42, t-tau, 
and p-tau) was used to create groups to increase the probability of an AD neuropathological substrate in 
the AD group, and to define the Pre-AD group (Table 1). 
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The AD group (N = 42) was defined according to the International Working Group (IWG)-2 criteria [14], 
requiring an AD-compatible CSF signature: decreased CSF Aβ42 levels plus high t-tau and p-tau levels. 
The Pre-AD group (N = 11) was defined according to the National Institute on Aging–Alzheimer's 
Association NIA-AA criteria [3], which include cognitive performance within the normal range 
(performance within 1.5 standard deviations) in all tests from a specific test battery, no significant 
psychiatric symptoms or previous neurological disease, and decreased CSF Aβ42. The control group (N = 
47) consisted of cognitively healthy individuals without cognitive deficits or biomarker-level 
abnormalities. Demographic data and APOE genotypes are shown in Table 1. 
Cerebrospinal Fluid Analysis 
Cerebrospinal fluid (CSF) was collected by lumbar puncture between 9 am and 12 am. Samples were 
processed within 1 hour by centrifugation at 4ºC for 10 min at 2000 × g, stored in polypropylene tubes, 
and frozen at -80ºC. Next, CSF Aβ42, p-tau, and t-tau levels were detected by enzyme-linked 
immunosorbent assay (ELISA) (Fujirebio Europe, Gent, Belgium). Biomarker cut-off values were 500 
pg/mL for Aβ42, 450 pg/mL for t-tau and 75 pg/mL for p-tau [15]. 
Whole Blood RNA Extraction 
Venous blood samples (3 mL) were drawn into Tempus Blood RNA tubes (Life technologies, Thermo 
Fisher Scientific, Waltham, MA, USA) and inverted 8–10 times. Tubes were frozen below −20ºC until 
RNA extraction. Total RNA was extracted using two Tempus tubes per subject and with the Tempus Spin 
RNA Isolation Kit (Life technologies) according to the manufacturer’s instructions. RNA was stored at 
−70ºC or below, then concentrated using the RNA Clean & Concentrator-5 Kit (Zymo Research, Irvine, 
CA, USA) and assessed for quality and quantity using the Nanodrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, Thermo Scientific, Waltham, MA, USA). 
Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) 
RNA (1 g) was retro-transcribed using the SuperScript® VILO™ cDNA synthesis kit following the 
manufacturer’s instructions (Life technologies). A pre-amplification of 14 cycles was performed for all 
genes with a customized TaqMan® PreAmp Pool and TaqMan® PreAmp Master Mix (Life technologies) 
prior to quantitative PCR. Custom TaqMan® Array Cards (TACs) were designed with three reference 
genes (PPIB, PGK1, POLR2A) and 20 selected genes, classified into the following groups: calcium 
signaling (7 genes), mitochondria/oxidative stress (8 genes), senescence and autophagy (3 genes), and AD 
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risk factor (2 genes) (Table 2). Reference genes for normalization were selected based on existing 
literature [16] and confirmed with a good stability score in Expression Suite software (Life technologies). 
Quantitative PCR with TACs was performed in a Viia7 instrument (Life technologies). All reactions were 
run in triplicate. 
Bioinformatics Analysis 
Quality control and statistical tests. Triplicate raw data cycle threshold (Ct) values of each sample were 
analyzed with Expression Suite software. These values were normalized with the mean Ct of the three 
endogenous genes (mean Ct value – mean Ct of endogenous genes = Ct value), and were further 
transformed to 2-Ct. After a careful exploration of the quality of the normalized data, a generalized linear 
model analysis (ANOVA), adjusted for covariates (age as quantitative and APOE genotype as 
cathegorical), was used to calculate differences in expression between groups.  P-values < 0.05 were 
considered significant. The magnitude of change between groups was calculated with the 2-Ct method 
(mean Ct value of group 1 – mean Ct value of group 2 = Ct, further transformed to 2-Ct). For the 
comparison of Pre-AD with controls or patients with AD, we selected groups of equal number (N = 11) 
matched for age. 
Pearson correlation and networks derivation. Pearson correlations between all genes were computed 
separately for both datasets, controls and patients with AD. Networks were constructed for any dataset 
and two genes were connected if their correlation was considered significant, having a p-value < 0.001. 
Representation of the networks  was accomplished with the Cytoscape© tool [17], an “open-source” 
platform which construct and manage networks. Finally, we performed a meta-analysis comparing the 
differences between the topology of the networks, mainly identifying differences on hubs (genes with a 
large number of connectivities). 
 
Results 
Differential gene expression 
Patients with AD presented significantly downregulated expression of BECN1 (p-value = 0.038; FC = 
0.88) and PRKCB (p-value = 0.024; FC = 0.85) genes compared with the control group (Fig. 1 A, B and 
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Fig. 2A). When using only age and not the APOE genotype as a covariate (ANOVA test), the CLU gene 
also reached statistical significance between these groups (p-value = 0.013). 
The Pre-AD group presented significant differences in the expression and up-regulation of the CDKN2A 
gene (p-value = 0.028; FC = 1.70) compared with an equal number of age-matched controls (Fig. 1 C and 
Fig. 2B). No significant differences in gene expression were detected between the matched Pre-AD and 
AD patient groups. 
Gene-gene expression correlations 
We looked for gene-gene expression correlations separately in the control (N = 47) and AD (N = 42) 
groups. Initially, we focused on large correlations (|R| > 0.7) in at least one of the two groups and 
highlighted those where a clear difference existed between groups: BECN1-S100A6 (only present in AD), 
and ATP2B1-MAP1S and ATP2B1-PPP3R1 (only present in controls) (Table 3). 
We then looked for all the correlations for the genes that were expressed statistically differently between 
AD and controls (BECN1 and PRKCB) with an |R| > 0.5 and p < 0.001 in at least one of the two groups. 
From these correlations, we identified three differences: BECN1-S100A6 (already mentioned above), 
BECN1-ATP2B1 (present in AD), and PRKCB-MAP1S (present in controls). In addition, seven more 
correlations were common in the two groups, mostly for the PRKCB gene (6/7) (Table 3). 
Cytoscape networks 
Correlations with |R| > 0.5 and p < 0.001 were represented with the Cytoscape© tool to visualize the 
networks for controls (Fig. 3A) and patients with AD (Fig. 3B). The network obtained for control subjects 
had largest coordination between the calcium-signaling and mitochondria/oxidative stress genes (12 
positive inter-correlations) than that obtained  for AD patients (7 positive inter-correlations ). Moreover, 
in the AD group, there were fewer connectivities between the mitochondria/oxidative stress genes 
compared with controls. We also identified gene hubs (largely connected genes) in both networks 
(ATP2B1, S100A6, CAPN1, PRKCB, and POLG), whereas other genes behaved as hub only in the 
controls and not in the patients with AD (PPP3R1, COX6B1, GPX3, and MAP1S). Finally, in the AD 
group, the links for the calcium-signaling gene, CACNA1B, were lost. Inversely, new correlations 
appeared for the senescence and autophagy genes for patients with AD (three genes with five 
correlations), with only one gene connected in controls. 
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Discussion 
We detected significant differences in the expression of three genes (BECN1, PRKCB, and CDKN2A) in 
the blood of patients with AD and Pre-AD. Compared with controls, we demonstrated that CDKN2A was 
expressed differently in the Pre-AD phase, while BECN1 and PRKCB were expressed differently in 
patients with AD. BECN1 and CDKN2A were related to the senescence and autophagy pathway, while 
PRKCB was related to the calcium-signaling pathway (http://pathcards.genecards.org/), although it can 
also play a role in autophagy and mitochondrial function [18]. Notably, these three genes are also 
considered tumor suppressor (CDKN2A and BECN1) or tumor promoter (PRKCB) genes 
(http://www.genecards.org/). 
A number of recent studies have revealed an inverse correlation in the prevalence of AD and cancer in 
multiple ethnic groups, with a reduced risk of developing cancer in patients with AD and a reduced risk of 
developing AD in those with a history of cancer [19]. In this sense, many genes regulating cell 
proliferation/survival or apoptosis are altered in AD brains, resulting in a prone-to-death state [20]. The 
re-expression of a multitude of cell-cycle regulators known to control the activation and progression of 
the cell cycle in dividing cells has been observed in degenerating AD neurons [21], suggesting a 
reactivation of the cell cycle during neurodegeneration [22-23,21]. After withdrawal from the cell cycle, 
differentiated neurons are able to alter molecular mechanisms that primarily control proliferation, to 
control synaptic plasticity instead [21,23]. The existence of these alternate effector pathways within a 
neuron might put it at risk and erroneously convert signals derived from plastic synaptic changes into 
positional cues that will activate the cell cycle. This cell-cycle activation can potentially link synaptic 
plasticity to cell death [21]. Indeed, aberrant reentry to the cell cycle may be an early pathogenic event of 
AD, and could be detectable in the brains of patients with mild cognitive impairment and pathological 
evidence of AD [24]. 
The CDKN2A gene codes for the Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) protein. It is a tumor 
suppressor gene involved in cell-cycle regulation, and is frequently mutated or deleted in several tumors. 
Interestingly, our study is the first to describe altered CDKN2A levels in the blood of patients with pre-
AD compared with controls. This suggests that CDKN2A could be considered as a potential biomarker or 
therapeutic target in the earlier stages of the disease; but, more evidence is needed using larger cohorts. 
The CDKN2A protein has previously been reported to be up-regulated in the brains of patients with AD 
[25], as well as in brain and peripheral cells from the amyloid precursor protein ⁄presenilin 1 mouse model 
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of AD [26]. However, we did not detect any differences in CDKN2A gene expression between our control 
and AD groups. This discrepancy from the previous studies could be explained by differences in the 
tissue/animal model studied and in the targeted molecule (mRNA or protein). Equally, the fact that we 
detected mRNA expression differences in the blood of the Pre-AD group makes us consider that it is 
possible to detect differences using this model. Thus, we hypothesize that the differences are bigger in the 
Pre-AD phase than when AD is present (with respect to controls), which would explain why we only have 
been able to detect them in blood of patients in the Pre-AD phase. Another possible explanation for this 
unexpected finding when comparing Controls and AD groups (with bigger sample size than the Pre-AD) 
would be the inter-individual variability in the values of CDKN2A expression within a group and the 
wider range of age. Other studies have revealed alterations of cell-cycle regulating proteins (p53, p21, 
phosphorylated forms p53 [ser15] and p21 [thr145], CDK2, E2F-1, Cyclin E, Rb and CDKN1B) in 
peripheral blood lymphocytes of patients with AD [27-29]. These studies, together with our findings, 
suggest that the use of peripheral cells to study the molecular basis of AD pathogenesis, including cell-
cycle disturbances, can be a valuable resource. 
The PRKCB gene encodes the beta protein of the Protein Kinase C (PKC) family of serine- and threonine-
specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. 
Although PKC over-expression has been shown to contribute to cell transformation, PKCs are not 
considered classic oncogenes that are activated by mutations, but are considered tumor promoters that 
enhance multiple cellular signaling pathways [30]. We have found evidence of PRKCB gene 
downregulation in patients with AD. However, the role of PRKCB in the development of AD is 
ambiguous, because some contradictory results exist as to whether it is up- or downregulated [31-33]. 
This could be explained by differences in studied tissue, mRNA or protein analysis, and experimental 
protocols. 
Autophagy is a major intracellular degradation pathway that plays an essential role in the cellular stress 
response. Autophagy degrades intracellular components, including whole organelles, allowing building 
blocks and energy to be released to maintain cellular homeostasis [34]. Several pathologies (including 
various types of cancer and neurodegenerative disorders such as AD) are characterized by altered levels 
of autophagy. The BECN1 gene, which encodes the Beclin-1 protein, is a tumor suppressor gene that 
participates in the regulation of autophagy and has an important role in development, tumor genesis, and 
neurodegeneration [35]. We identified BECN1 downregulation in patients with AD, consistent with 
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previous literature that have indicated that expression of the Beclin-1 protein is reduced in the brains of 
patients with AD [12,36]. We have been unable to identify any data concerning its expression in the 
blood. 
Several reports have described increased CLU protein concentration in different brain areas. However, 
there is some controversy as to whether it is increased in the frontal cortex in AD and whether it is 
associated with the APOE 4 load [37-40]. Moreover, increased plasma CLU concentration has been 
reported in AD to predict greater beta amyloid (Aβ) burden in the medial temporal lobe [41] as well as 
brain atrophy in mild cognitive impairment [42]. We analyzed the differences in CLU gene expression in 
the blood, but it only reached statistical significance when using age as a covariate (p-value = 0.013), with 
a trend when using APOE as a covariate (p-value = 0.07). Thus, the APOE genotype may be important 
when considering CLU levels as a possible biomarker. The role of CLU should be explored in more depth 
to clarify its potential role as a blood biomarker. 
Gene expression correlation networks were created for the 20 genes selected for this study. Although they 
represent a small proportion of the genome, we detected different correlations between the control group 
and patients with AD. These could represent functional relations that are gained or lost in patients with 
AD, and that could be targets for research or therapy. Gene-gene significant correlations present in 
controls only (i.e., PRKCB-MAP1S, ATP2B1-MAP1S, and ATP2B1-PPP3R1), and not in patients with 
AD, could describe important relationships for healthy aging. Conversely, gene-gene significant 
correlations present only in patients with AD (i.e., BECN1-S100A6 and BECN1-ATP2B1) could be 
important for the development of the disease or could be a consequence of the disease. Some genes were 
hubs (largely interconnected features) only in one of the groups, but the PRKCB gene was a hub in both 
networks, and had a relatively high number of connectivities with genes involved in mitochondrial 
function, such as POLG, GPX3, MAP1S, and COX6B1. In this sense, many inter-correlations exist 
between calcium-signaling and mitochondria/oxidative stress functional groups, with a higher number in 
controls than in patients with AD. While the correlations were present in both networks (controls and AD) 
for the calcium-signaling genes, the correlations were diminished in the AD network for the 
mitochondria/oxidative stress genes, which indicates that the uncoupling of genes from these functional 
groups could be relevant for the disease state. 
We are aware that the present study has some limitations. First, our Pre-AD group had a reduced sample 
size because it was difficult to identify potential subjects that met all the inclusion criteria. Second, when 
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assessed in blood, gene expression may be influenced by the cellular diversity of the blood compartment; 
several additional factors can contribute to the individual variability in gene expression, such as diet, 
exercise, treatment or inflammatory events. Finally, for the genes with a statistically significant 
difference, there exists an overlap among participant groups, which makes them unsuitable for use as 
diagnostic biomarkers. Nevertheless, we believe that they are very useful for continue to advance our 
knowledge of the physiopathology of AD. 
In conclusion, we studied the expression of genes in the peripheral blood at different stages of AD. We 
detected significant differences in the expression of genes related to calcium signaling, senescence and 
autophagy. Notably, all identified genes were related to cancer, strengthening the argument that more 
studies are needed to investigate the relationship between neurodegenerative diseases and cancer. Due to 
its accessibility, whole blood represents a valuable tissue that can be used to advance our knowledge of 
the pathophysiology of AD and, potentially, to find a biomarker for AD. 
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TABLES 
Table 1. Demographic and clinical/biochemical characteristics of participants, divided in the main three 
groups: Controls, AD (Alzheimer’s disease patients) and Pre-AD (Preclinical AD) 
 
 Control AD Pre-AD 
n 47 42 11 
Gender 
(Male/Female) 
17/30 13/29 2/9 
Age (years) 
63.58 
(7.2) 
66.14 
(8.5) 
69.59 
(8.3) 
APOE (% ε4) 14.9 54.76 27.27 
MMSE score 
28.55 
(1.5) 
23.03 
(5.2) 
27.55 
(1.4) 
CSF Aβ42 
(pg/mL) 
799.12 
(213.3) 
371.30 
(75.9) 
389.83 
(96.8) 
CSF t-tau 
(pg/mL) 
237.81 
(67.0) 
844.50 
(360.9) 
280.58 
(164.0) 
CSF p-tau 
(pg/mL) 
52.21 
(10.7) 
115.23 
(47.8) 
59.74 
(27.0) 
 
 
 
Values are shown as mean (± SD) for age, MMSE score, and CSF AD biomarkers. APOE genotype is 
given as the percentage of ε4 allele carriers (% ε4). Key: CSF, cerebrospinal fluid  
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Table 2. Details of the selected genes 
Gene symbol Description 
Group 
classification 
Life technologies 
assay number 
CALM3 
Calmodulin 3 
(phosphorylase kinase, 
delta) 
Calcium signaling Hs00968732_g1 
CACNA1B 
Calcium Channel, Voltage-
Dependent, N Type, Alpha 
1B Subunit 
Calcium signaling Hs01053090_m1 
PPP3R1 
Protein Phosphatase 3, 
Regulatory Subunit B, Alpha 
Calcium signaling Hs01547793_m1 
ATP2B1 
ATPase, Ca++ Transporting, 
Plasma Membrane 
Calcium signaling Hs00155949_m1 
PRKCB Protein Kinase C, Beta Calcium signaling Hs00176998_m1 
CAPN1 Calpain 1 Calcium signaling Hs00559804_m1 
S100A6 
S100 calcium binding 
protein A6 
Calcium signaling Hs00170953_m1 
BECN1 Beclin-1, autophagy related 
Senescence and 
autophagy  
Hs00186838_m1 
ATG5 Autophagy related 5  
Senescence and 
autophagy 
Hs00169468_m1 
CDKN2A 
Cyclin-dependent kinase 
inhibitor 2A 
Senescence and 
autophagy 
Hs02902543_mH 
CLU Clusterin AD risk factor gene Hs00971656_m1 
BIN1 Bridging Integrator 1 AD risk factor gene Hs00184913_m1 
HSD17B10 
Hydroxysteroid (17-beta) 
dehydrogenase 10 
Mitochondria and 
oxidative stress 
Hs00189576_m1 
POLG 
Polymerase (DNA directed), 
gamma 
Mitochondria and 
oxidative stress 
Hs01018668_m1 
MAP1S 
Microtubule-associated 
protein 1S 
Mitochondria and 
oxidative stress 
Hs00430193_m1 
COX6B1 
Cytochrome c oxidase 
subunit VIb polypeptide 1 
(ubiquitous) 
Mitochondria and 
oxidative stress 
Hs00266375_m1 
GPX3 glutathione peroxidase 3  
Mitochondria and 
oxidative stress 
Hs01078668_m1 
SOD1 
Superoxide dismutase 1, 
soluble 
Mitochondria and 
oxidative stress 
Hs00533490_m1 
TOMM40 
Translocase of outer 
mitochondrial membrane 40 
homolog 
Mitochondria and 
oxidative stress 
Hs00746704_s1 
PPARGC1A 
Peroxisome proliferator-
activated receptor gamma, 
coactivator one alpha 
Mitochondria and 
oxidative stress 
Hs01016719_m1 
POLR2A 
Polymerase (RNA) II (DNA 
directed) polypeptide A 
Reference gene Hs01108291_m1 
PPIB Peptidylpropyl isomerase B Reference gene Hs00168719_m1 
PGK1 Phosphoglycerate kinase 1 Reference gene Hs00943178_g1 
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Table 3. Correlations between the control and AD groups 
Correlation R Controls p-value 
Controls 
R AD p-value AD 
Largest different correlations (|R| > 0.7) 
ATP2B1-MAP1S 0.73 3.18E-09 -0.08 0.59 
ATP2B1-PPP3R1 0.82 3.91E-13 0.39 0.007 
BECN1-S100A6 0.38 0.007 0.71 1.96E-08 
 
BECN1 and PRKCB different correlations (|R| > 0.5) 
BECN1-ATP2B1 -0.21 0.14 -0.6 0.00044 
PRKCB-MAP1S 0.55 3.51E-05 0.06 0.7 
 
BECN1 and PRKCB common correlations (|R| > 0.5) 
BECN1-CLU 0.51 0.00019 0.5 0.00036 
PRKCB-COX6B1 0.63 1.18E-06 0.45 0.0013 
PRKCB-POLG 0.61 2.13E-06 0.61 5.26E-06 
PRKCB-GPX3 0.78 2.63E-11 0.66 3.99E-07 
PRKCB-S100A6 -0.59 7.81E-06 -0.62 2.27E-06 
PRKCB-PPP3R1 0.66 2.51E-07 0.51 0.00024 
PRKCB-ATP2B1 0.69 2.78E-08 0.62 2.72E-06 
 
Strong correlations (|R| > 0.7) are shown between controls and AD groups. Correlations between PRKCB 
and BECN1 genes, with p < 0.001 and |R| > 0.5, were common (present in both groups) or different 
(present only in controls or AD). |R| value and p-value are shown per group. Abbreviations: AD: 
Alzheimer’s disease. 
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FIGURE LEGENDS 
 
Fig. 1 Gene expression levels in peripheral blood (a.u.: arbitrary units; 2-Ct*1000) of the three 
significantly different genes: A) BECN1; B) PRKCB; C) CDKN2A. Mean ± 95% confidence intervals 
(CI) and significant p-values are shown. Key: CTRLs, Controls (N = 47 for BECN1 and PRKCB; N = 11 
for CDKN2A); Pre-AD, patients with preclinical AD (N = 11); AD, patients with Alzheimer’s disease (N 
= 42) 
 
Fig. 2 Fold-change (2-Ct) of the 20 genes that were studied. A) Comparison of AD (N = 42) and controls 
(N = 47). B) Comparison of pre-AD and controls (N = 11). Key, CTRLs, Controls; AD, Alzheimer’s 
disease 
 
Fig. 3 Cytoscape networks representing significant correlations for gene-gene expression. Continuous 
lines represent positive correlations and discontinuous lines represent negative correlations. The thickness 
of the line is proportional to the strength of the correlation. Colors represent the functional group 
classification of a gene: yellow, calcium signaling; purple, mitochondria/oxidative stress; blue, 
senescence and autophagy; red, risk factor genes for Alzheimer’s disease 
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